Vaxcyte PCVX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Vaxcyte (PCVX) Business Model and Operations Summary
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Key Insights
Vaxcyte (PCVX) Core Market Data and Business Metrics
Latest Closing Price
$32.23Market Cap
$4.23 BillionPrice-Earnings Ratio
-8.48Total Outstanding Shares
128.76 Million SharesTotal Employees
414Dividend
No dividendIPO Date
June 12, 2020SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
825 Industrial Road, Ste. 300, San Carlos, CA, 94070
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities | $-2.01 Billion |
| Net Cash Flow From Financing Activities, Continuing | $2.45 Billion |
| Net Cash Flow From Investing Activities, Continuing | $-2.01 Billion |
| Net Cash Flow | $-9.36 Million |
| Net Cash Flow From Financing Activities | $2.45 Billion |
| Net Cash Flow, Continuing | $-9.79 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Income/Loss From Continuing Operations After Tax | $-463.93 Million |
| Basic Earnings Per Share | $-3.80 |
| Revenues | $0 |
| Depreciation and Amortization | $7 Million |
| Operating Expenses | $569.55 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-4.05 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-467.98 Million |
| Comprehensive Income/Loss Attributable To Parent | $-467.98 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $-4.05 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Non-current Assets | $1.53 Billion |
| Wages | $20.55 Million |
| Noncurrent Liabilities | $65.32 Million |
| Prepaid Expenses | $15.73 Million |
| Equity Attributable To Parent | $3.31 Billion |
| Equity | $3.31 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||